Krajina: Írsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
Escitalopram
Primecrown 2010 Limited
N06AB; N06AB10
Escitalopram
15 milligram(s)
Film-coated tablet
Product subject to prescription which may not be renewed (A)
Selective serotonin reuptake inhibitors; escitalopram
Authorised
2011-05-20
LEXAPRO ® 15MG FILM-COATED TABLETS escitalopram PACKAGE LEAFLET: INFORMATION FOR THE USER WHAT IS IN THIS LEAFLET: 1. What Lexapro is and what it is used for 2. What you need to know before you take Lexapro 3. How to take Lexapro 4. Possible side effects 5. How to store Lexapro 6. Contents of the pack and other information 1. WHAT LEXAPRO IS AND WHAT IT IS USED FOR Lexapro contains the active substance escitalopram. Lexapro belongs to a group of antidepressants called selective serotonin reuptake inhibitors (SSRIs). These medicines act on the serotonin-system in the brain by increasing the serotonin level. Disturbances in the serotonin-system are considered an important factor in the development of depression and related diseases. Lexapro is used to treat depression (major depressive episodes) and anxiety disorders (such as panic disorder with or without agoraphobia, social anxiety disorder, generalised anxiety disorder and obsessive- compulsive disorder). It may take a couple of weeks before you start to feel better. Continue to take Lexapro, even if it takes some time before you feel any improvement in your condition. You must talk to a doctor if you do not feel better or if you feel worse. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LEXAPRO DO NOT TAKE LEXAPRO • if you are allergic to escitalopram or any of the other ingredients of this medicine (listed in section 6). • if you take other medicines which belong to a group called MAO inhibitors, including selegiline (used in the treatment of Parkinson’s disease), moclobemide (used in the treatment of depression) and linezolid (an antibiotic). • if you are born with or have had an episode of abnormal heart rhythm (seen at ECG; an examination to evaluate how the heart is functioning). • if you take medicines for heart rhythm problems or that may affect the heart’s rhythm (see section 2 “Other medicines and Lexapro”). WARNINGS AND PRECAUTIONS TALK TO YOUR DOCTOR OR PHARMACIST BEFORE TAKING LEXAPRO. Please tell your doctor if you have any other conditi Prečítajte si celý dokument
Health Products Regulatory Authority 17 December 2018 CRN008LSW Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lexapro 15 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 15 mg escitalopram (as oxalate) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated Tablets _Product imported from France:_ Oval, white, scored, film-coated tablet marked with “EM” on one side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS As per PA0805/002/003 5 PHARMACOLOGICAL PROPERTIES As per PA0805/002/003 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Tablet core: Microcrystalline cellulose Colloidal anhydrous silica Talc Croscarmellose sodium Magnesium stearate Coating: Hypromellose Macrogol 400 Titanium dioxide (E 171) Health Products Regulatory Authority 17 December 2018 CRN008LSW Page 2 of 2 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf life expiry date of this product is the date shown on the blister strips and outer carton of the product as marketed in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE No special precautions for storage. 6.5 NATURE AND CONTENTS OF CONTAINER Over-labelled carton containing two transparent blister strips (14 tablets per strip) Pack size of 28 tablets 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER Primecrown 2010 Limited 4/5 Northolt Trading Estate Belvue Road Northolt Middlesex UB5 5QS United Kingdom 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA1633/14/3 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 th May 2011 10 DATE OF REVISION OF THE TEXT December 2018 Prečítajte si celý dokument